SCHEMBL21061670

SCHEMBL21061670

CC(C)(C)OC(=O)NC(CC(=O)O)Cc1cc(C(F)(F)F)ccc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ FFAR2 O15552 1/20 0.39
▸ MME P08473 1/20 0.39
▸ PIN1 Q13526 1/20 0.39
▸ CFTR P13569 1/20 0.38
▸ AAK1 Q2M2I8 2/20 0.37
▸ SCN9A Q15858 1/20 0.36
▸ FFAR1 O14842 1/20 0.36
▸ EEF2K O00418 1/20 0.36
▸ CTSS P25774 2/20 0.36
▸ CTSK P43235 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ RXRA P19793 2/20 0.36
▸ NR1H2 P55055 2/20 0.36
▸ NR1H3 Q13133 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18428119 0.86 ATM (0.43) ATMMMEAAK1CTSSCTSK
SCHEMBL1509251 0.86 FFAR1 (0.48) PPARGPPARAATMFFAR2MME
SCHEMBL4562743 0.86 FFAR1 (0.48) PPARGPPARAATMFFAR2MME
SCHEMBL18428089 0.85 ATM (0.42) PPARGPPARAATMMMEAAK1
SCHEMBL29500819 0.84 CTSL (0.42) PPARGPPARAATMMMEAAK1
SCHEMBL18427996 0.83 ATM (0.41) PPARGPPARAATMMMEAAK1
SCHEMBL18428052 0.83 ATM (0.43) PPARGPPARAATMAAK1CTSS
SCHEMBL29500919 0.83 MEN1 (0.41) PPARGPPARAATMFFAR2MME
SCHEMBL1519752 0.82 FFAR2 (0.54) PPARGPPARAATMFFAR2MME
SCHEMBL29163526 0.82 FFAR2 (0.54) PPARGPPARAATMFFAR2MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3724192-B1 TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2022-08-03 — — EP disclosed
US-11298363-B2 Triazolobenzazepines as vasopressin V1a receptor antagonists RICHTER GEDEON NYRT. (HU) 2022-04-12 — — US disclosed
EP-3724192-A1 TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS Richter Gedeon Nyrt. (HU) 2020-10-21 — — EP disclosed
WO-2019116324-A1 TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2019-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11298363-B2 Triazolobenzazepines as vasopressin V1a receptor antagonists AVPR1B, AVPR1A, AVPR2 PPARG 775/4885PPARA 637/4885ATM 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback